GSRGT 2020: The Need for Perioperative Management Strategies: Role of Clinical Oncologists - Chemotherapy
(UroToday.com) The penile cancer session at the Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit included a discussion for the role of chemotherapy in the perioperative management of patients with penile cancer by Dr. Guru Sonpavde from the Dana-Farber Cancer Institute. Dr. Sonpavde notes that surgery alone for patients with locally advanced disease is associated with high-risk of recurrence, both locoregionally and distant, with 5-year overall survival (OS) rates of 0-42%. Particularly bad predictors include bulky inguinal adenopathy of ≥ 4cm, bilateral nodes, pelvic lymphadenopathy (N3 disease), an unresectable primary tumor (T4), and extranodal extension.
GSRGT 2020: Aggressive Surgical Approach for Nodal Disease
(UroToday.com) As part of the penile cancer session at the inaugural Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit, Dr. Maarten Albersen from Belgium discussed aggressive surgical approaches for managing patients with nodal disease. Dr. Albersen notes that risk of nodal metastasis is based on the European Association of Urology (EAU) risk delineation:
EAU good risk (pT1G1): 0% risk
EAU intermediate risk (pT1G2): 9% risk
EAU high risk (≥ pT2, G3, or LVI): 23% risk
Indeed, appropriate staging of the inguinal lymph nodes is crucial to management. Dynamic sentinel biopsy is one option but has a high false-negative rate outside of high-volume centers. The National Comprehensive Cancer Network (NCCN) guidelines suggest that 20 procedures performed annually should be the baseline, with a steep learning curve of ~30-50 cases. Comparatively, inguinal lymph node dissection has a low false-negative rat
GSRGT 2020: Penile Cancer: Conservative N-strategies - Minimally Invasive Staging of the Groin
(Urotoday.com) The penile cancer session at the inaugural virtual summit of the Global Society of Rare Genitourinary Tumors (GSRGT) included a presentation of conservative strategies for lymph node management, including minimally invasive staging of the groin, by Dr. Oscar Brouwer from The Netherlands Cancer Institute. Dr. Brouwer notes that penile cancer survival is highly dependent on lymph node status and that appropriate management of the regional lymph nodes is crucial for patient survival. Older studies suggest that early resection of occult metastasis versus resection after the disease is palpable during surveillance significantly improves cancer-specific survival (84% vs 35% at 3 years). As such, detecting lymphatic spread as early as possible is crucial. Dr. Brouwer notes that if there are palpable abnormalities of the groin, there is no place for a trial of antibiotics and clin
Lancet Oncology. In the DESTINY-Breast01 trial, trastuzumab deruxtecan demonstrated clinically meaningful and durable activity in patients who had received two or more prior anti-HER2 therapies. The safety and tolerability profile of trastuzumab deruxtecan seen in DESTINY-Breast01 was consistent with that observed in the phase 1 trial.
An updated analysis from DESTINY-Breast01, reinforcing the durable efficacy and long-term safety and tolerability profile of trastuzumab deruxtecan, was presented earlier this week at the 2020 San Antonio Breast Cancer Symposium (SABCS).
“We are encouraged by the CHMP positive opinion given the significant unmet need for patients with HER2 positive metastatic breast cancer,” said Gilles Gallant, BPharm, PhD, FOPQ, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo. “Trastuzumab deruxtecan is already available for patients with HER2 positive metastatic breast cancer in the U.S. and Japan, and we are now one st
Daiichi Sankyo Company, Limited: Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo Company, Limited
(hereafter, Daiichi Sankyo) and AstraZeneca s trastuzumab deruxtecan has been recommended for conditional marketing authorization in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens.
In Europe, approximately 520,000 cases of breast cancer in women are diagnosed annually, with roughly one in five cases being HER2 positive.
1,2 The impact of the disease is significant, with breast cancer responsible for more than 137,000 deaths per year.